Frontlight ResearchEarly access
Active, not recruitingPhase 1
Single-ascending Dose Study of Kylo-12 in Healthy Subjects
Key facts
- Who runs it
- Kylonova (Xiamen) Biopharma co., LTD.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 50 people, planned
- Started
- 12 Mar 2025
- Ended
- 30 Aug 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Kylo-12
- Placebo
- Record updated
- 16 March 2026
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Men and women aged 18 to 55 years old, inclusive
- Body mass index (BMI) between 19 kg/m2 and 30 kg/m2, inclusive
- Protocol-defined elevated serum TG level
- Female subjects must not be able to get pregnant and male subjects must agree to adhere to contraception restrictions
- Willing to comply with protocol required visits and assessments, and provide written informed consent
Who cannot take part
- Received an investigational drug, vaccine or device within 3 months before dosing
- History of alcohol abuse within 12 months before dosing
- History of drug abuse within 3 months before screening
- History of blood donations or blood loss of 400 ml and more within 3 months before dosing
- History of stroke or myocardial infarction within 6 months before sceening
- History or evidence of a clinically significant disorder, condition or disease
- History of evidence of malignant tumor or Gilbert syndrome
- Positive screen of Hepatitis B surface antigen, hepatitis C virus, human immunodeficiency virus or syphilis infection
- Pregnant or breast-feeding women
- Other exclusion criteria applied per protocol
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. Kylo-12 will be evaluated in approximately 50 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.
The 2 groups in the trial
- Kylo-12Treatment being tested
Single ascending doses of Kylo-12 administered subcutaneously (SC).
- PlaceboPlacebo, for comparison
Administered SC.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Kylo-12 in Healthy Subjects
- Record updated
- 16 March 2026